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and Sue L Lightman3,4Abstract
Background: To report the outcome of oral valacyclovir as the sole antiviral therapy for patients with acute retinal
necrosis (ARN).
Methods: This study reports a retrospective, interventional case series of nine consecutive patients with ten eyes with
newly diagnosed ARN treated with oral valacyclovir as the sole antiviral agent. Eight patients received oral valacyclovir 2 g
tid (Valtrex, GlaxoSmithKline) and one patient with impaired renal function received oral 1 g tid. The main outcome
measures were response to treatment, time to initial response to treatment, time to complete resolution of retinitis, best
corrected visual acuity (BCVA) at final follow-up, retinal detachment and development of recurrent or second eye disease.
Results: Retinitis resolved in ten of ten (100%) affected eyes. The median time to initial detectable response was seven
days and the median time to complete resolution was 21 days. A final BCVA of 20/40 or better was achieved in 6/10
(60%) of eyes. 3/10 eyes (30%) developed a retinal detachment. No patients developed either disease reactivation or
second eye involvement over the course of the study (mean follow up 31 weeks, range 7 to 104 weeks).
Conclusions: Treatment with oral valacyclovir as the sole antiviral therapy resulted in complete resolution of retinitis.
Final BCVA and retinal detachment rate were comparable with previously reported outcomes for intravenous acyclovir.
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Acute retinal necrosis (ARN) is a rare, but potentially dev-
astating, syndrome characterised by progressive peripheral
necrotising retinitis. It was first described in 1971 [1], but
it took more than a decade later for its herpetic aetiology
to be discovered and antiviral therapy to become the
mainstay of treatment [2,3]. The current standard of care
for ARN consists of intravenous acyclovir 10 mg/kg (or
1500 mg/m2) every 8 h for 5–10 days, followed by oral
acyclovir 400-800 mg 5 times daily for an additional
6-12 weeks, to reduce the risk of second eye involvement
[4]. Nevertheless, there is a lack of consensus concerning
the treatment of ARN, with an increasing number of
groups reporting primary treatment of ARN with oral
antiviral therapy alone [5-10], although others suggest that
intravenous antiviral therapy is superior [11] or even that* Correspondence: s.r.taylor@imperial.ac.uk
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reproduction in any medium, provided the orhigher doses of intravenous therapy are indicated in most
patients without renal impairment [12].
Advocates of oral antiviral therapy argue that the adop-
tion of intravenous antiviral therapy predated the discov-
ery of valacyclovir and famciclovir, both of which have
superior plasma bioavailability to acyclovir as oral prepara-
tions [13]. Both agents have been reported to be successful
in the treatment of ARN in small case series [5-8,14]. This
study adds to this evidence and is, to our knowledge, the
largest consecutive case series of patients with ARN trea-
ted solely with oral valacyclovir without antecedent intra-
venous therapy or adjunctive intravitreal therapy.
Methods
The study consisted of a retrospective review of the
medical records of nine consecutive patients who pre-
sented between December 2006 and November 2009 at
a single tertiary referral centre with a new diagnosis of
ARN and whose antiviral therapy consisted solely of oral
valacyclovir. This study was approved by the Research
Governance Committee of Moorfields Eye Hospitaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of ARN was based on the diagnostic criteria established by
the American Uveitis Society, which consist of: (1) one or
more discrete foci of peripheral retinal necrosis; (2) occlu-
sive retinal vasculitis; (3) acute panuveitis; (4) circumferen-
tial disease spread; (5) rapid progression of disease in the
absence of treatment [15]. All patients had active, not
indolent disease, as defined by the presence of significant
uveitis. In three out of nine cases, the clinical diagnosis
was confirmed by demonstration of herpetic viral DNA in
aqueous or vitreous samples by polymerase chain reaction
(PCR); in the remaining six cases, the diagnosis of pre-
sumed herpetic retinitis was made on the basis of the
above clinical diagnostic criteria alone.
The extent of retinal involvement was recorded using
the same classification scheme as for cytomegalovirus
retinitis [16]. In this scheme, zone 1 comprises a circle
with a 3000 μm radius centred on the fovea, with an ex-
tension 1500 μm nasally from the optic nerve head, zone
2 extends from the anterior border of zone one to the
equator, and zone 3 extends anteriorly from the equator
to the ora serrata.
All patients were treated as outpatients. Patients received
oral valacyclovir 2 g tid (Valtrex, GlaxoSmithKline), unless
there was evidence of renal impairment, in which case the
dose was reduced to 1 g tid, and were treated for a mini-
mum duration of 6 weeks. Where there was significant
vitritis or optic nerve involvement, such that visual acuity
was impaired, systemic corticosteroid therapy at a dose
of 0.5-1 mg/kg was instituted on the same day as antiviral
therapy, and was tapered over the course of the antiviral
therapy. Renal function was monitored closely throughout
treatment. Prophylactic laser treatment consisted of three
consecutive rows of confluent and circumferential laser
applied to normal retina posterior to the edge of the nec-
rotic retina, and was performed if there was adequate
visualisation of the fundus and sufficient uninvolved retina
to allow application of laser without endangering the optic
nerve or macula.
Outcome measures included time to clinical response,
time to complete resolution of retinitis and best cor-
rected visual acuity (BCVA) at the final follow-up visit.
Clinical response was defined as the fading of areas of
retinitis. Complete resolution was defined as the total
disappearance of active retinitis and vasculitis, together
with evidence of retinal pigment epithelial atrophy or
pigmentation. The development of retinal detachment,
and the occurrence of second eye involvement or disease
reactivation were also assessed.
Results
The study included ten eyes of nine patients; one patient
with HIV co-infection which was being successfully trea-
ted with HAART (CD4 count > 500 cells/mm3 andundetectable viral load) presented with disseminated
herpes zoster virus infection and bilateral ARN. Patient
and disease characteristics and the results of treatment
are summarised in Table 1. The median age at disease
onset was 38 years (range 30 to 82 years) and the mean
duration of symptoms prior to presentation was 14 days
(range 1 to 28 days). Two patients were HIV positive
(patients 6 and 8) but the remaining seven patients did
not have a history suggestive of underlying immune dys-
function. All ten eyes had at least one discrete focus of
peripheral retinal necrosis. Four eyes had zone two dis-
ease and three eyes had zone one disease. Three eyes
had prominent vitritis and two of these eyes also had
optic disc oedema.
Varicella zoster virus (VZV) was identified as the most
likely causative virus in five eyes of four patients. Two
cases were proven on PCR, and it was the presumed cause
in two further patients, one of whom had disseminated
herpes zoster at the time of presentation (patient 8) and
one of whom had a history of recent chicken pox infection
(patient 2). One patient had HSV-2 infection proven by
PCR, and one patient was presumed to have HSV-1 infec-
tion owing to a past history of HSV-1 encephalitis.
All patients were treated with oral valacyclovir for at least
six weeks. One patient with HIV infection and dissemi-
nated VZV was advised to remain on maintenance therapy,
but was lost to follow up after seven weeks. Maintenance
therapy was discussed with the patient who had had HSV
encephalitis as an infant, but this was declined.
The median time to initial response was 7 days (range
7-14 days) and retinitis completely resolved in all ten
eyes (100%) in a median 21 days (range 7-42 days). Rep-
resentative images from three patients are included in
Figure 1. Four patients received adjunctive systemic cor-
ticosteroids, and one patient received a single orbital
floor injection of 40 mg triamcinolone as an alternative
to systemic corticosteroid therapy at presentation. Six
eyes were treated with prophylactic barrier laser; this
was not possible in three eyes as they had zone one dis-
ease and, in one case, laser was considered unnecessary
owing to the area of retinitis being small.
6/10 eyes (60%) achieved a final BCVA of 20/40 or
better, but 2/10 eyes (20%) were 20/200 or worse by final
follow-up. Three eyes developed retinal detachments at
35-49 days following initiation of treatment. Two
patients underwent pars plana vitrectomy, endolaser and
silicone oil, and one patient declined surgical interven-
tion. There was no evidence of disease reactivation or
second-eye involvement over the follow-up period of a
median 31 weeks (range 7-104 weeks).
Discussion
In this series, we report the results of treatment of ARN
with oral valacyclovir, and believe this to be the largest
Table 1 Clinical findings and response to treatment with oral valacyclovir
Patient Age, Sex Eye Virus Posterior
extent
(zone)
Time to
initial
response
(weeks)
Time to
complete
resolution
(weeks)
Initial
BCVA
Final
BCVA
Laser Steroids Complications
1 79, M R Undetermined 1 1 5 20/200 20/40 No – Zone 1 OFSI RPE change at macula
2 39, M L Presumed VZV 3 1 1 20/20 20/20 No – Zone 1 No Nil
3 82, M R VZV on PCR 1 1 4 20/120 CFs Yes Oral prednisolone RD at 45 days
4 54, F L VZV on PCR 2 2 6 CFs 20/60 Yes Oral prednisolone Nil
5 36, M R HSV-2 on PCR 2 1 3 20/30 20/80 Yes Oral prednisolone RD at 35 days
6 36, M L Undetermined 3 1 3 20/20 20/16 No No Nil
7 33, M L Presumed HSV-1 1 2 5 HMs LP No – Zone 1 Oral prednisolone RD at 49 days
8 30, F R Presumed VZV 3 1 2 20/20 20/20 Yes No Nil
L Presumed VZV 2 1 2 20/30 20/20 Yes No Nil
9 81, M L Undetermined 2 1 6 20/20 20/40 Yes Oral prednisolone Nil
VZV = Varicella zoster virus; HSV = Herpes simplex virus; PCR = polymerase chain reaction; BCVA = best corrected visual acuity; CFs = count fingers; HMs = hand
movements; LP = perception of light; OFSI = Orbital floor corticosteroid injection; RD = retinal detachment.
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proved effective at treating retinitis in all ten eyes, and
the median times to initial response and complete reso-
lution of retinitis were 7 days and 21 days respectively,
which is similar to the results of other series in which
intravenous acyclovir [2,17] or other oral antiviral agents
[5] were used. Similarly, 60% of our patients achieved a
final BCVA of 20/40 or better and 20% had a final BCVA
of 20/200 or worse; both comparable with previous
reported series of oral antiviral agents [5,17] and intra-
venous acyclovir [18-20].
We recorded no cases of fellow eye involvement. The
natural history of ARN is for some two thirds of fellow
eyes to become involved, although intravenous acyclovir
has reduced this to 3-14% [14,18,19,21-23]. Other series
in which oral antiviral agents were used have also failed
to report fellow eye involvement [5], but involvement
can occur decades later [24,25], so longer follow upFigure 1 Representative images from three patients with acute retina
antiviral therapy. Images from the top row are pre-treatment and correspwould be required to confirm this finding. 30% of our
patients developed a retinal detachment. The natural
history of ARN is for 75% of affected eyes to progress to
retinal detachment [26], the reported rate with intraven-
ous acyclovir being reduced to 20-52% [14,17-20,22].
Most retinal detachments occur within six months of
presentation [14], and 6 of 8 patients in our series had
follow-up longer than six months, suggesting that the
rate is unlikely to be significantly underreported.
There is a wide variation in the reported 50% inhibi-
tory concentrations (IC50) of acyclovir in vitro – 0.02 to
13.5 μM for HSV-1, 0.01 to 9.9 μM for HSV-2, and 0.12
to 10.8 μM for VZV [27-29]. Administration of oral vala-
cyclovir 1 g tid has been shown to achieve plasma con-
centrations in excess of the IC50 for most clinical
isolates of HSV-1, HSV-2 and VZV throughout the dos-
age period [28], as has administration of famciclovir
500 mg tds [30], but this dose still only achieves dailyl necrosis treated with oral valacyclovir 2 g tds as their sole
ond to post-treatment images in the bottom row.
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values similar to those obtained with intravenous acyclo-
vir 5 mg/kg tid [31,32]. In contrast, valacyclovir 2 g tid
produces a daily AUC of 109 μg·h-1 mL-1 which is simi-
lar to that achieved by intravenous acyclovir 10 mg/kg
tid at 107 μg·h-1 mL-1 [33].
We treated our patients with oral valacyclovir 2 g tid
on the basis that this would achieve AUC values similar
to intravenous acyclovir 10 mg/kg tid without exposing
patients to the side-effects associated with higher doses
of valacyclovir, which include the development of
thrombotic microangiopathy [34], and without com-
promising patient compliance throughout a long treat-
ment duration [35]. The 2 g tid dose was well tolerated
in our patients, and no patient developed systemic ad-
verse effects associated with treatment [32,35].
Limitations of this study include its retrospective na-
ture and small sample size, which mean that it is not
possible to comment on the efficacy or otherwise of oral
prednisolone or prophylactic barrier laser. The short
duration of follow up may also skew incidence rates for
reactivation of disease, fellow eye involvement and ret-
inal detachment. Nevertheless, treatment with oral vala-
cyclovir 2 g tid appears to be as efficacious as previously
reported outcomes with other antiviral treatments, and
suggests that this is a valid treatment option for patients
with acute retinal necrosis.
Conclusions
Treatment with oral valacyclovir 2 g tid appears to be as
efficacious as previously reported outcomes with other
antiviral treatments, and suggests that this is a valid
treatment option for patients with acute retinal necrosis.
Competing interest
SRJT was supported by the UK National Institute of Health Research and by
the Imperial NIHR Comprehensive Biomedical Research Centre. The authors
report no conflicts of interest.
Authors’ contribution
ST and SL designed the study. RH, CY, ST, LJ and NG collected data. ST, LJ
and JM performed data analysis. RH, CY and NG drafted the manuscript. ST,
LJ, JM and SL revised the manuscript. All authors read and approved the
final manuscript.
Summary
This study reports the outcome of oral valacyclovir as the sole antiviral
therapy in ten eyes of nine patients with acute retinal necrosis. Retinitis
resolved in all affected eyes and 60% of eyes achieved 20/40 or better. The
retinal detachment rate was 30%, but no patients developed disease
reactivation or second eye involvement.
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